Ray Barlow, SynOx Therapeutics CEO
April 22, 2024 03:30 AM EDT
Financing

Irish biotech col­lects $75M in Se­ries B to start Phase 3 rare joint tu­mor tri­al

Ayisha Sharma

News Reporter

Syn­Ox Ther­a­peu­tics has com­plet­ed a $75 mil­lion Se­ries B raise to ad­vance its mon­o­clon­al an­ti­body drug through a reg­is­tra­tional tri­al for a type of non …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times